Table 4.
Univariate and Multivariate Analyses for irAE (Existence of irAEs vs Absence) With Binary Logistic Regression Analysis.
| Covariates (n for univariate analysis*) | Univariate analysis (n = 200) | Multivariate analysis (n = 194) | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P-value | OR | 95% CI | P-value | |
| Gender (female (73) vs male (127)) | .63 | .35-1.13 | .12 | --- | --- | --- |
| Age (≥75 (44) vs <75 (156)) | 2.70 | 1.25-5.84 | .01 | 3.55 | 1.55-8.14 | .003 |
| Smoking (yes (139) vs no (60)) | 2.31 | 1.25-4.29 | .01 | 2.75 | 1.41-5.36 | .003 |
| BMI (≥18.5 (153) vs <18.5 (47)) | 1.66 | .86-3.21 | .13 | --- | --- | --- |
| Number of metastatic sites | .83 | .67-1.04 | .11 | --- | --- | --- |
| Metastasis | ||||||
| Brain (with (22) vs without (178)) | .76 | .31-1.85 | .55 | --- | --- | --- |
| Lung (with (86) vs without (114)) | 1.54 | .86-2.74 | .15 | --- | --- | --- |
| Liver (with (61) vs without (139)) | .51 | .28-.94 | .03 | --- | --- | --- |
| PS (≥2 (33) vs <2 (167)) | .36 | .16-.76 | .01 | --- | --- | --- |
| Therapy line (≥3 (95) vs <3 (105)) | .58 | .33-1.03 | .06 | --- | --- | --- |
| Baseline ANC (198) | .99 | .90-1.08 | .74 | --- | --- | --- |
| Baseline ALC (198) | 1.32 | .80-2.18 | .28 | --- | --- | --- |
| Baseline PLT (198) | 1.00 | 1.00-1.00 | .59 | --- | --- | --- |
| Baseline ALB (≥3.5 (108) vs <3.5 (86)) | 2.18 | 1.21-3.91 | .01 | 2.47 | 1.32-4.60 | .004 |
| Baseline CRP (≥1.0 (75) vs <1.0 (121)) | .75 | .42-1.35 | .34 | --- | --- | --- |
| Baseline LDH (≥400 (23) vs <400 (172)) | .46 | .19-1.10 | .08 | --- | --- | --- |
| NSCLC (vs others) (50) | 1.54 | .78-3.03 | .21 | --- | --- | --- |
| Gastric cancer (vs others) (43) | .48 | .24-.95 | .04 | --- | --- | --- |
| Melanoma (vs others) (38) | .87 | .43-1.79 | .72 | --- | --- | --- |
OR: odds ratio, 95% CI: 95% confidence interval, P-value: P-value by regression analysis. *Sums of n are not necessarily 200 because of missing data.